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Original Article
Introduction
Our study is a New York Medical College institutional 
review board–approved retrospective study. In all the 
cases of suspected sexually transmitted infection (STI), 
it is mandated by New York State to test for syphilis in 
addition to testing for gonorrhea and chlamydia. In fact, 
it is customary practice to draw a blood sample for syph-
ilis for all sexually active adolescents who come for rou-
tine annual physical examination.1 The prevalence of 
syphilis seroreactivity in the general population is 
believed to be low (0.71%).2 Our study aims to deter-
mine whether it is cost-effective to screen for syphilis in 
cases of suspected gonorrhea and chlamydia.
Materials and Methods
The emergency department charts from January 2004 
to August 2006 were reviewed for the following test 
results: gonorrhea DNA probe, chlamydia DNA probe, 
and syphilis IgG (immunoglobulin G)/RPR (rapid 
plasma reagin).
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Abstract
Background. In all cases of suspected sexually transmitted infections (STIs), it has been routine practice to screen 
for syphilis with a blood sample. The incidence of syphilis seems to be lower than that of commonly screened 
STIs. Objective. The objective of our study was to determine whether it is cost-effective to screen for syphilis 
with serological testing in cases of suspected gonorrhea and chlamydia infections. Hypothesis. Our hypothesis 
is that it is not cost-effective to screen for syphilis in cases of presumed gonorrhea and chlamydia infections. 
Methods. Our study is a New York Medical College institutional review board–approved retrospective study. 
During the period January 2004 to August 12, 2006, the laboratory work of all patients tested for gonorrhea 
and chlamydia in our emergency department was reviewed. The charts were reviewed for the following tests: 
gonorrhea DNA probe, chlamydia DNA probe, and syphilis IgG (immunoglobulin G)/RPR (rapid plasma reagin). 
The results of these tests were obtained and analyzed. Results. The total number of patients screened for 
gonorrhea and chlamydia during this period was 196. Seventy-eight patients tested positive for gonorrhea and 
chlamydia. All these 78 patients, tested negative for syphilis. The overall prevalence of positivity for STIs was 
39.8% (78/196). The prevalence of chlamydia alone was 85.9% (67/78) and gonorrhea alone was 7.69% (6/78). 
The prevalence of combined both chlamydia and gonorrhea was 6.4% (5/78). Statistics. We used online SILICO 
2 × 4 Fisher exact test. By comparing positive and negative results of serology RPR, GC, and chlamydia trap, the 
resultant 2-tailed P value is <.0001, which is statistically significant. Conclusions. Per our study, the yield of syphilis 
testing was negligible. It may not be cost-effective to screen for syphilis in cases of STIs such as gonorrhea and 
chlamydia.
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Results
A total of 196 patients were screened for gonorrhea, 
chlamydia, and syphilis during the above-mentioned 
period. Seventy-eight patients tested positive for gonor-
rhea and/or chlamydia. All these 78 patients tested nega-
tive for syphilis. The overall prevalence of combined 
gonorrhea and chlamydia was 39.8% (78/196). Among 
positive testings, the prevalence of chlamydia alone was 
67/78 (85.9.%), and that of gonorrhea alone was 6/78 
(7.69%). The combined prevalence of both gonorrhea 
and chlamydia in patients was 5/78 (6.4%). The total 
number of patients screened for gonorrhea, chlamydia, 
and syphilis during the above-mentioned period was 
196. All 196 patients tested negative for syphilis; Of 196 
tested, 78 patients tested positive for gonorrhea and 
chlamydia either combined or alone was 39.8%(78/196). 
The combined prevalence of gonorrhea and chlamydia 
was 3% (6/196), whereas that of chlamydia alone was 
67/196 (34%; and gonorrhea alone was 6/196 (3.06%) 
see Table 1 and Figure 1).
Statistics
We used online SILICO 2 × 4 Fisher exact test. By com-
paring positive and negative results of serology RPR, 
GC, and chlamydia trap, the resultant 2-tailed P value is 
<.0001, which is statistically significant.
Discussion
According to the World Health Organization, there are 
12 million new cases of syphilis annually worldwide. 
Most patients who have syphilis are asymptomatic, and 
serological testing is required to make a diagnosis. Per 
the Centers for Disease Control and Prevention (CDC), 
US syphilis rates declined to an all-time low in 2000 
(2.2 cases per 100 000 cases). Marion County, Indiana, 
had the highest incidence with 37.1 cases per 100 000 
population. The incidence of gonorrhea is declining 
(113.5 cases per 100 000), whereas the incidence of 
chlamydia (319.6 per 100 000) is rising per the CDC 
November 2005 data.
The CDC reports increased incidence of syphilis in 
black men (7.7 cases per 100 000 in 2004), and the inci-
dence of syphilis among women remained the same at 
0.8 cases per 100 000. The CDC also reported that the 
incidence of chlamydia cases was 3.3 times higher 
among women than men in 2004.
The US Preventive Services Task Force (USPSTF) 
concluded the following: No direct evidence exists that 
screening for syphilis infection leads to improved health 
outcomes in persons at increased risk. Routine screening 
of asymptomatic persons is not recommended in patients 
not at increased risk for syphilis infection. There is no 
evidence supporting routine screening for syphilis in 
patients diagnosed with other sexually transmitted dis-
eases. The potential harm of screening (cost, false-posi-
tive tests, and stigma) in a low incidence population 
outweighs the benefits.3
The USPSTF does not recommend routine screening 
for syphilis in asymptomatic low-risk individuals. But 
according to the USPSTF, persons diagnosed with chla-
mydia, gonorrhea, or genital herpes are at higher risk for 
acquiring syphilis and they recommend screening for 
syphilis in these individuals.
Per authors Swygard et al, screening for syphilis is 
recommended for commercial sex workers, persons in 
correctional facilities, persons diagnosed with another 
STD, men who have sex with men who engage in high-
risk behavior, and all pregnant women at the first prena-
tal visit.4
According to Risser et al, the syphilis rate in south-
ern states is 4.3 cases per 100 000 persons. Rates per 
Table 1. Data Summary.










Combined GC and 
Chlamydia Positive Probes

















No Syphilis GC CH GC/CH
Figure 1. Data summary.
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100 000 persons for syphilis in 2006 were 4.9 among 
African American; 0.8 among Hispanic women, and 0.3 
among white women; these rates were in 2020, respec-
tively, 24.5, 4.0, and 1.5, that is, 13 time greater than the 
Healthy People.5
According to the CDC, during 1998 to 2002, the 
number of syphilis cases among 16 men who have sex 
with men (MSM) in San Francisco increased from 8 to 
512 per 100 000 MSM.6
Syphilis testing is not cost-effective in detecting 
syphilis in HIV-negative blood donors. Each year 18 
million dollars is spent on serological tests for syphilis, 
with another extra cost of 3.9 20 million dollars spent on 
discarding specimens.7
Wangnapi et al reported, in pregnant women in 
Papua, New Guinea, that the prevalence of Chlamydia 
trachomatis was 11.1%, Neisseria gonorrhoeae 9.7%, 
and Trichomonas vaginalis 21.3%. Risk factors included 
having a partner at perceived risk of infection, maternal 
extramarital intercourse, early sexual debut, lack of for-
mal education, urban residence, smoking, and women 
not using condoms.8
Kenyon et al found out that in most populations, 
antenatal syphilis prevalence (ASP) dropped to under 
1% before 1960. In Zimbabwe and black South Africans, 
ASP was high in the pre-penicillin period, dropped in 
the post-penicillin period, but then plateaued at around 
6% until the end of the 20th century.9
Ballah and colleagues indicated that strengthening 
current surveillance systems for syphilis is important to 
track and monitor disease burden. Usage of routinely 
collected laboratory information to generate surveil-
lance was proposed in South Africa; annually for the 
period from 2003 to 2012 there was an approximate 
14% reduction of syphilis seroprevalence.10
Smith and Angarone reported that STIs remain a sig-
nificant burden on public health in the United States. 
Primary prevention counseling with early diagnosis and 
treatment remain the best methods to decrease the inci-
dence of STIs. Smith and Angarone conclude that 
through significant public heath interventions, the inci-
dence of gonorrhea, chlamydia, and trichomonas is 
decreasing, but surprisingly the incidence of primary 
and secondary syphilis is increasing.11
Nuñez-Forero et al tried to determine the diagnostic 
accuracy of tests developed for use at the point of care 
for Chlamydia trachomatis (CT), Neisseria gonor-
rhoeae (NG), and syphilis in women having symptoms 
of lower urinary tract infection. According to the authors, 
rapid tests studies are not useful for screening for NG at 
the point of care. But, in pregnant women, rapid tests 
has been recommended for chlamydia and syphilis. In 
the case of CT, a recommendation about their use in 
routine care should be supported by a cost-effectiveness 
analysis. In screening populations, such as people at 
high risk of STIs or pregnant women, the RTs for syphi-
lis were recommended.12
The National Profile STD Surveillance summarizes 
that the national rate of syphilis cases reached an his-
toric low in 2000 and 2001, but has increased almost 
every year since then. This increase was largely attribut-
able to an increase among men, and among MSM. 
However, during 2013 to 2014, rates increased among 
both men and women in every region of the country. 
Rates of reported congenital syphilis cases also increased 
in every region of the country during 2013 to 2014.
MSM continued to account for most P&S (primary 
and secondary) syphilis cases in 2014. Nationally, the 
highest rates of P&S syphilis in 2014 were observed 
among men aged 20 to 24 years and 25 to 29 years, 
among men in the West and in the South, and among 
black men.13
The CDC in their 2014 Surveillance report has 
reported that cases of chlamydia, gonorrhea, and syphi-
lis have increased for the first time since 2006. In 2014, 
there were 350 062 reported cases of gonorrhea (a rate 
of 110.7 per 100 000) and 19 999 reported cases of P&S 
syphilis (for a rate of 6.3 per 100 000). Sexually trans-
mitted diseases continue to affect young people—par-
ticularly women—most severely, but increasing rates 
among men contributed to the overall increases in 2014 
across all 3 diseases. To reduce Sexually transmitted 
diseases, Americans must take steps to protect them-
selves. For sexually active individuals, testing and 
treatment according to CDC’s recommendations, using 
condoms consistently and correctly, and limiting the 
number of sex partners are all effective strategies for 
reducing the risk of infection and consequences to 
health.14
Our study concurs with recommendations in other 
studies. Even though syphilis is on the rise in certain 
populations and USPSTF recommends serological tests 
for syphilis, it is evident from our study that the yield is 
poor or negligible and hence it is not a cost-effective 
screening procedure.
Limitations
The limitation of our study is the small sample size.
Conclusions
Per our study, the yield of syphilis testing was negligi-
ble. It was not cost-effective to screen for syphilis ($4 
per test for RPR) in all cases of suspected gonorrhea and 
chlamydia.
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